First-in-Human Study of RGT-419B Alone and With Endocrine Therapy in Subjects With HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: RGT-419B|DRUG: RGT-419B in combination with hormonal therapy
Sponsor: Regor Pharmaceuticals Inc.